Asymmetric dimethylarginine (ADMA) is an endogenous competitive inhibitor of nitric oxide synthase and is independently associated with poor cardiovascular outcomes. However, the direct relationship between serum ADMA level and the extent of subclinical coronary atherosclerotic plaque has never been investigated. In total, 130 consecutive asymptomatic Taiwanese subjects (mean age, 55.6±10 years), who received a health screening evaluation, were enrolled. Coronary plaque detected by computed tomography coronary angiography (CTCA) was observed in 85 (65.4%) of 130 individuals. Patients with coronary plaque had a higher ADMA level (1.16±1.15 μmol/L vs. 0.42 ± 0.33 μmol /L, p

Original languageEnglish
Pages (from-to)236-243
Number of pages8
JournalImmunology, Endocrine and Metabolic Agents in Medicinal Chemistry
Issue number3
Publication statusPublished - 2012


  • Asymmetric dimethylarginine (ADMA)
  • Asymptomatic
  • Atherosclerotic plaque
  • Computed tomography coronary angiography (CTCA)
  • Coronary atherosclerosis
  • Endothelial dysfunction
  • Nitric oxide (NO)

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Immunology and Allergy
  • Pharmacology


Dive into the research topics of 'The association between serum asymmetric dimethylarginine and coronary atherosclerotic plaque in an asymptomatic population'. Together they form a unique fingerprint.

Cite this